Amalgamated Financial’s Vanda Pharmaceuticals VNDA Stock Holding History

Amalgamated Financial’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$279K	Buy	+24,696	New	+$325K	﹤0.01%	1765

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

EIP

Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Amalgamated Financial's VNDA Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Vanda Pharmaceuticals (VNDA) in Q1 2022: 24,696 shares worth $279K. The stake represents ﹤0.01% of the portfolio and ranks #1765 among its holdings.

188 funds tracked by Wall St. Rank hold VNDA as of Q1 2022.

Amalgamated Financial held 24,696 shares of Vanda Pharmaceuticals worth $279K as of Q1 2022.
Vanda Pharmaceuticals was a new Amalgamated Financial position in Q1 2022.
Vanda Pharmaceuticals made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #1765 holding.
188 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.